ATH 33.3% 0.4¢ alterity therapeutics limited

successful capital raising, page-11

  1. 5,921 Posts.
    lightbulb Created with Sketch. 151
    HaHa PW. If all results come in as planned, and are positive, in that efficacy is demonstrated against Huntington's disease, making it the first disease modifying drug for Huntington's, and a solid confirmation of the previous Ph2 cognition efficacy is seen along with plaque reduction and other biomarkers, you may see two ABomb sized binary events, which will indeed create a new level of support. Maybe a little above 20c.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.